Article

CKD-602. Chong Kun Dang.

Stichting Apotheek Haarlemse Ziekenhuizen, Boerhaavelaan 24, 2035 RC Haarlem, Amsterdam, The Netherlands.
Current opinion in investigational drugs (London, England: 2000) (Impact Factor: 3.55). 01/2004; 4(12):1455-9.
Source: PubMed

ABSTRACT Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.

1 Bookmark
 · 
52 Views